Vertex Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS, and when can generic versions of VERTEX PHARMS drugs launch?
VERTEX PHARMS has eight approved drugs.
There are forty-nine US patents protecting VERTEX PHARMS drugs.
There are seven hundred and eighty-two patent family members on VERTEX PHARMS drugs in fifty-four countries and eighty-four supplementary protection certificates in nineteen countries.
Drugs and US Patents for Vertex Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-005 | May 3, 2023 | RX | Yes | No | 8,883,206 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | 10,239,867 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-001 | Aug 7, 2018 | RX | Yes | No | 11,564,916 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Vertex Pharms Inc | SYMDEKO (COPACKAGED) | ivacaftor; ivacaftor, tezacaftor | TABLET;ORAL | 210491-001 | Feb 12, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vertex Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | 8,529,882 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expirations for VERTEX PHARMS
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Try a Trial | ⤷ Try a Trial |
International Patents for Vertex Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 2774925 | ⤷ Try a Trial |
South Korea | 101331768 | ⤷ Try a Trial |
Denmark | 1878720 | ⤷ Try a Trial |
Serbia | 55559 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2404919 | C02404919/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE (LUMACAFTOR); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65981 02.09.2016 |
2826776 | CA 2021 00013 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) ....; REG. NO/DATE: EU/1/18/1306 20181106 |
1320540 | CR 2012 00007 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TELAPREVIR OG FARMACEUTISK ACCEPTABLE SALTE OG/ELLER SOLVATER AF TELAPREVIR ELLER SOLVATER AF SADANNE SALTE; REG. NO/DATE: EU/1/11/720/001 20110919 |
1773816 | 237 5014-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: N-(5-HYDROXY-2,4-DITERC-BUTYL-FENYL)-4-OXO- -1H-CHINOLIN-3-KARBOXAMID (IVACAFTOR); REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.